Overview

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
Phase:
PHASE2
Details
Lead Sponsor:
Adaptimmune